Myelodysplastic Syndrome (MDS) Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Myelodysplastic Syndromes Information Center has current, evidence-based information for you. Get the facts about myelodysplastic syndromes early detection, treatment, and survivorship, and stay up to date with ongoing myelodysplastic syndromes research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Myelodysplastic Syndrome Community is the leading Social Media Application for Myelodysplastic Syndrome patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Get informed and get connected! OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine
Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition... Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk
Evidence of a connection between thiopurines and myeloid disorders in IBD patients
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Myelodysplastic Syndrome Management
Sean Swarner is a master of setting a goal and achieving it. So when he... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Myelodysplastic Syndrome Clinical Trials
ECOGE1905 – A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia.
DACO-020 – Phase 2 study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Advanced-Stage Myelodysplastic Syndromes
REFMAL39 – A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Weekly for Three Consecutive Weeks of 28-Day Cycle in Patients with Solid Tumors